Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of QL1706 Combined With Neoadjuvant Endocrine Therapy in Patients With HR-Positive/HER2-Negative Breast Cancer Showing a Poor Response to Neoadjuvant Chemotherapy: A Prospective, Randomized Controlled Clinical Trial

NCT07782840 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT07782840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07782840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of QL1706 Combined With Neoadjuvant Endocrine Therapy in Patients With HR-Positive/HER2-Negative Breast Cancer Showing a Poor Response to Neoadjuvant Chemotherapy: A Prospective, Randomized Controlled Clinical Trial
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 1, 2028
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer